Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vancomycin.

J E Geraci, P E Hermans

    Mayo Clinic Proceedings
    |February 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Vancomycin, an antibiotic effective against resistant staphylococci, remains crucial for serious infections. Its future use includes methicillin-resistant Staphylococcus aureus and Clostridium difficile infections.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis.

    Journal of hepatology·1993
    Same author

    Pneumocephalus due to barotrauma: CT demonstration.

    AJR. American journal of roentgenology·1992
    Same author

    Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation.

    Hepatology (Baltimore, Md.)·1992
    Same author

    Early diagnosis of cytomegalovirus hepatitis in liver transplant recipients: role of immunostaining, DNA hybridization and culture of hepatic tissue.

    Hepatology (Baltimore, Md.)·1990
    Same author

    Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations.

    The Journal of infectious diseases·1989
    Same author

    Bacterial infections after liver transplantation.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·1989
    Same journal

    Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

    Mayo Clinic proceedings·2026
    Same journal

    RAAS Inhibition in the ICU: Stop, Continue, or Restart?

    Mayo Clinic proceedings·2026
    Same journal

    Chronic Kidney Disease-In the Limelight, July 2026.

    Mayo Clinic proceedings·2026
    Same journal

    In Reply: Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

    Mayo Clinic proceedings·2026
    Same journal

    Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

    Mayo Clinic proceedings·2026
    Same journal

    Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.

    Mayo Clinic proceedings·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Microbiology

    Background:

    • Vancomycin, a narrow-spectrum bactericidal antibiotic, was introduced in 1956 to combat penicillin-resistant staphylococci.
    • Its initial role was treating serious staphylococcal infections when alternatives were limited.
    • The advent of semisynthetic penicillins and cephalosporins shifted vancomycin to an alternative therapy.

    Purpose of the Study:

    • To review the historical efficacy and evolving role of vancomycin.
    • To highlight potential future applications of vancomycin in treating resistant bacterial infections.

    Main Methods:

    • Historical review of vancomycin's introduction and usage.
    • Analysis of clinical scenarios necessitating vancomycin therapy.

    Related Experiment Videos

    Main Results:

    • Vancomycin demonstrated efficacy against penicillinase-producing staphylococci.
    • Its use decreased with newer antibiotics but is resurging for resistant strains.

    Conclusions:

    • Vancomycin remains a vital antibiotic for specific serious infections.
    • Future applications include methicillin-resistant Staphylococcus aureus, streptococcal endocarditis, prosthetic device infections, and Clostridium difficile-associated enterocolitis.